SEARCH

Search Details

Takashima Yuta

Hokkaido University Hospital Internal MedicineAssistant Professor

Researcher basic information

■ Degree
  • 博士(医学), 北海道大学
■ URL
researchmap URLホームページURL■ Various IDs
Researcher number
  • 90848764
J-Global ID■ Research Keywords and Fields
Research Keyword
  • 気管支鏡
  • 肺癌
  • 呼吸器
Research Field
  • Life Science, Respiratory medicine
■ Educational Organization

Career

■ Career
Career
  • Jul. 2020 - Present
    Hokkaido University, Hokkaido University Hospital, 助教
Educational Background
  • Apr. 2015 - Mar. 2019, Hokkaido University, Graduate School of Medicine
  • Apr. 2003 - Mar. 2009, Iwate Medical University, School of Medicine

Research activity information

■ Papers
  • Comparison of anthracycline plus platinum versus other platinum-based regimens as first-line chemotherapy for untreated thymoma: A retrospective cohort study (NEJ023B).
    Go Saito; Ryo Ko; Yuki Shiko; Kohei Takahashi; Yoshiaki Nagai; Risa Ebina-Shibuya; Kazutoshi Isobe; Kazuhiro Nishiyama; Hiroshi Wakui; Yuta Takashima; Kei Sonehara; Shoko Shimamura; Kyoichi Kaira; Yoshiro Nakahara; Hironori Ashinuma; Hiromi Nagashima; Yohei Suzuki; Kei Chubachi; Jun Sugisaka; Kana Watanabe; Takehiro Tozuka; Shosei Ro; Kakeru Hisakane; Takaaki Sasaki; Hiroyuki Sakashita; Shigeo Hanada; Makoto Maemondo; Kunihiko Kobayashi; Takehito Shukuya
    Lung cancer (Amsterdam, Netherlands), 217, 109456, 109456, Jul. 2026, [International Magazine]
    English, Scientific journal, BACKGROUND: Optimal management of advanced thymoma remains uncertain. We compared the efficacy of first-line platinum-anthracycline chemotherapy with other platinum-based regimens in a large Japanese cohort. METHODS: We retrospectively analyzed 157 patients with unresectable or recurrent thymoma treated at 39 institutions (2000-2020). Regimens were categorized as platinum-anthracycline (n = 104) or non-anthracycline platinum (n = 53). Propensity score matching (PSM) balanced baseline characteristics (46 pairs). The primary endpoint was overall response rate (ORR); secondary endpoints were real-world progression-free survival (rwPFS) and overall survival (OS). RESULTS: Median age was 58 years (24-79) and 53% were male; 62% had recurrent disease. Before PSM, ORR was higher with platinum-anthracycline than with non-anthracycline platinum (57% vs 31%; p = 0.0024), while rwPFS (median 15.0 vs 13.4 months; HR 1.07; p = 0.72) and OS (median 84.9 vs 111.9 months; HR 1.36; p = 0.24) did not differ. After PSM, ORR remained higher (58% vs 32%; p = 0.0014) with comparable rwPFS (12.1 vs 11.7 months; HR 0.98; p = 0.98) and OS (93.8 vs 113.5 months; HR 1.41; p = 0.31). Overall, 70% of patients received subsequent local therapy. Among fatal cases, paraneoplastic syndromes occurred in 50%, and infections and cardiovascular events were frequent causes of death in addition to tumour progression. CONCLUSIONS: Although platinum-anthracycline regimens achieved higher response rates, this did not translate into longer rwPFS or OS. Non-anthracycline platinum regimens may be reasonable for selected patients, particularly when treatment tolerability is a priority, within individualized multidisciplinary long-term management. TRIAL REGISTRATION: UMIN000048181.
  • Clinical characteristics of long-term survivors of small cell lung cancer.
    Yuki Hatakeyama; Daisuke Morinaga; Jun Sakakibara-Konishi; Riku Azuma; Kosuke Tsuji; Shotaro Ito; Tomohiko Nakamura; Yuta Takashima; Tetsuaki Shoji; Megumi Furuta; Tomohiro Goda; Hidenori Kitai; Yasuyuki Ikezawa; Satoshi Konno
    Respiratory investigation, 64, 4, 101468, 101468, Jul. 2026, [International Magazine]
    English, Scientific journal, BACKGROUND: Small cell lung cancer (SCLC) is an aggressive disease with poor prognosis. Long-term survivors (LTS) are rare, and factors associated with LTS remain unclear. This study investigated the characteristics and treatment outcomes of LTS with SCLC. METHODS: Patients diagnosed with SCLC who received systemic therapy between 2007 and 2025 were retrospectively reviewed. LTS were defined as those surviving ≥18 months. Baseline clinical features, laboratory data, and treatment outcomes were compared between LTS and non-LTS. RESULTS: Among 217 patients, 60 were LTS. LTS were younger and had better performance status, recurrence after surgery or chemoradiotherapy, fewer liver and bone metastases, fewer metastatic organs, lower tumor burden, and lower neutrophil-to-lymphocyte ratios (NLR). In the multivariate analysis, younger age, lower tumor burden, and lower NLR were independently associated with LTS. The proportion of LTS did not differ between patients treated with or without immune checkpoint inhibitors (ICIs). LTS showed significantly longer progression-free survival (PFS) after first-line therapy and also maintained longer PFS across second- to fourth-line treatments, indicating sustained chemosensitivity. ICI-containing regimens tended to improve PFS and overall survival in both groups, though the degree of benefit varied. CONCLUSIONS: LTS with SCLC were characterized by favorable baseline features, particularly younger age, lower tumor burden, and lower NLR, as well as sustained responsiveness to later-line chemotherapy.
  • Amivantamab-Associated Vasculitis in a Patient With EGFR Exon 20 Insertion Non-Small Cell Lung Cancer: A Case Report.
    Daisuke Morinaga; Megumi Furuta; Doppo Fukui; Yuki Matsuura; Yukiko Yoshida; Shotaro Ito; Yuta Takashima; Hidenori Kitai; Zenichi Tanei; Jun Sakakibara-Konishi; Satoshi Konno
    Clinical lung cancer, 27, 2, 117, 120, Mar. 2026, [International Magazine]
    English, Scientific journal
  • Limited-Stage Small-Cell Lung Cancer With Severe Paraneoplastic Limbic Encephalitis Successfully Treated With Chemoradiotherapy Followed by Immune Checkpoint Inhibitor Maintenance Therapy: A Case Report.
    Daisuke Morinaga; Hidenori Kitai; Hanko Sato; Doppo Fukui; Wataru Harabayashi; Yukiko Yoshida; Shotaro Ito; Yuta Takashima; Megumi Furuta; Akihiko Kudo; Shintaro Fujii; Hisashi Uwatoko; Hiroaki Yaguchi; Keiko Tanaka; Ichiro Yabe; Jun Sakakibara-Konishi; Satoshi Konno
    Clinical lung cancer, 27, 2, 121, 125, Mar. 2026, [International Magazine]
    English, Scientific journal
  • A case of synchronous multiple primary lung cancers each harboring an EGFR mutation or an ALK fusion gene alone that responded to osimertinib with chemotherapy.
    Doppo Fukui; Daisuke Morinaga; Jun Sakakibara-Konishi; Yukiko Yoshida; Masahiro Kashima; Shotaro Ito; Megumi Furuta; Yuta Takashima; Zenichi Tanei; Satoshi Konno
    Respiratory investigation, 64, 2, 101375, 101375, 20 Jan. 2026, [International Magazine]
    English, Scientific journal, A comprehensive pathological evaluation is useful for diagnosing synchronous multiple primary lung cancer (sMPLC). However, a consensus regarding treatment for sMPLC with different driver mutations is lacking. We present a case of sMPLC harboring an epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) fusion gene. For the advanced EGFR-positive tumor, osimertinib plus chemotherapy was initiated, the latter also covering ALK-positive tumor. A marked response and slight reduction occurred in the EGFR-positive and ALK-positive tumors, respectively. Surgical resection of the ALK-positive tumor achieved negative margins. Targeted therapy with chemotherapy may effectively treat sMPLC with different driver mutations.
  • Severe psoriasis as an immune-related adverse event after long-term atezolizumab therapy for pulmonary large-cell neuroendocrine carcinoma: A case report.
    Chisa Murayama; Yasuyuki Ikezawa; Chihiro Shiiya; Yoshitaka Oda; Masafumi Ikezawa; Akihiro Matsunaga; Kosuke Tsuji; Tetsuaki Shoji; Megumi Furuta; Yuta Takashima; Hidenori Kitai; Jun Sakakibara-Konishi; Satoshi Konno
    Respiratory medicine case reports, 61, 102421, 102421, 2026, [International Magazine]
    English, Scientific journal, Immune checkpoint inhibitors, such as atezolizumab, have become integral to the treatment of various malignancies and have significantly improved clinical outcomes by enhancing host antitumor immune responses. However, with their expanding clinical use, immune-related adverse events (irAEs) have been increasingly recognized. These events may involve any organ system and pose new challenges in patient management. Most irAEs occur within the first few months following treatment initiation; however, they may also develop unexpectedly after prolonged periods of stable therapy. Late-onset irAEs are generally mild to moderate in severity, although a subset can progress to severe forms. Dermatological toxicities are the most frequently observed irAEs. Although most cutaneous reactions are mild and manageable, severe skin toxicities, although relatively uncommon, can substantially impair patients' quality of life and may necessitate treatment modification or discontinuation. Psoriasis is a recognized cutaneous irAE that may present either as a de novo disease in patients without a history of psoriasis or as an exacerbation of pre-existing psoriasis. This case report describes a rare presentation of severe psoriasis that developed following long-term atezolizumab therapy and improved following treatment with oral prednisolone in 61-year-old man with pulmonary large-cell neuroendocrine carcinoma.
  • Atezolizumab長期投与中に免疫関連有害事象による乾癬を呈した肺大細胞神経内分泌癌の1例
    村山 千咲; 池澤 靖元; 池澤 将文; 福井 独歩; 吉田 有貴子; 松永 章宏; 森永 大亮; 辻 康介; 伊藤 祥太郎; 庄司 哲明; 古田 恵; 高島 雄太; 北井 英典; 榊原 純; 今野 哲; 椎谷 千尋; 小田 義崇
    肺癌, 65, 7, 1093, 1094, (NPO)日本肺癌学会, Dec. 2025
    Japanese
  • Successful treatment of huntingtin-interacting protein-1-anaplastic lymphoma kinase-positive lung cancer with severe airway stenosis using silicone stent placement and alectinib.
    Yuma Sato; Hidenori Kitai; Yuta Takashima; Naofumi Shinagawa; Jun Sakakibara-Konishi; Hiroya Ohkawa; Kanako C Hatanaka; Yutaka Hatanaka; Hiroshi Yokouchi; Satoshi Konno
    Respiratory investigation, 63, 6, 1365, 1368, Nov. 2025, [International Magazine]
    English, Scientific journal, Huntingtin-interacting protein 1 (HIP1)-anaplastic lymphoma kinase (ALK) is a relatively rare fusion in ALK-positive lung cancers. HIP1-ALK (H19:A20) is a rare variant among HIP1-ALK-positive lung cancers, and data on the efficacy of ALK tyrosine kinase inhibitors are limited. We report a 37-year-old man with HIP1-ALK (H19:A20) lung adenocarcinoma treated with silicone stent placement and alectinib. Stent placement was effective in improving symptoms, and the best treatment response with alectinib was a partial response. Routine ALK screening using IHC or comprehensive genomic profiling should be considered for patients with lung cancer with suspected ALK gene.
  • Atezolizumab長期投与中に免疫関連有害事象による乾癬を呈した肺大細胞神経内分泌癌の1例
    村山 千咲; 池澤 靖元; 椎谷 千尋; 小田 義崇; 池澤 将文; 福井 独歩; 吉田 有貴子; 松永 章宏; 森永 大亮; 辻 康介; 伊藤 祥太郎; 庄司 哲明; 古田 恵; 高島 雄太; 北井 秀典; 榊原 純; 今野 哲
    肺癌, 65, 5, 671, 671, (NPO)日本肺癌学会, Nov. 2025
    Japanese
  • Prospective multicenter validation of a next-generation sequencing panel using cytology specimens for lung cancer: cPANEL.
    Kei Morikawa; Yuta Takashima; Masahide Oki; Akifumi Tsuzuku; Shuji Murakami; Daisuke Minami; Shinji Fujii; Naofumi Shinagawa; Fumihiro Asano; Seiji Nakamura; Yoshiharu Sato; Yumi Ueda; Fumihiko Suzuki; Tomoyuki Yokose; Kenichiro Tanabe; Masamichi Mineshita
    BMC cancer, 25, 1, 1538, 1538, 09 Oct. 2025, [International Magazine]
    English, Scientific journal, BACKGROUND: There are no prospective studies to estimate whether cytology specimens can replace tissue samples using lung cancer gene panel analysis. We evaluated the success rate of gene panel testing and nucleic acid yield and quality when using cytology specimens for lung cancer over tissue specimens. METHODS: In this prospective study, clinical cytology specimens collected via transbronchial brushing, needle aspiration washing, and pleural effusion were stored in a nucleic acid stabilizer. The primary endpoint was the superior success rate of gene analysis using cytology specimens over the conventional success rate using tissue specimens. RESULTS: The full analysis set included 248 cases. The success rate for gene panel analysis using cytology specimens was 98.4% (95% confidence interval (CI), 95.9-99.6%) with a positive concordance rate of 97.3% (95% CI, 90.7-99.7%) by other companion diagnostic kits. The median value for nucleic acid yield and quality (DNA/RNA integrated number) of cytology specimens was 546.0/426.5 ng and 9.2/4.7 for DNA/RNA, respectively. The Pearson correlation coefficient of variant allele frequency between tissue formalin-fixed and paraffin-embedded (FFPE) sample and cytology specimens for mutant cases was 0.815. The ratio of double-stranded to total DNA showed that cytology specimens were of significantly higher quality than FFPE specimens. CONCLUSIONS: The success rate of cytology specimens in gene analysis was significantly higher than conventional data. Because of the sufficient nucleic acid yield, high quality, and high correlation of mutant allele frequency compared to FFPE specimens, cytology specimens are suitable for panel testing as tissue substitutes. TRIAL REGISTRATION: UMIN Registry UMIN000047215 (cPANEL trial).  https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000053766 .
  • Evaluating the Efficacy of Thin Convex-probe Endobronchial Ultrasound Bronchoscope in Cadaveric Models.
    Yuta Takashima; Naofumi Shinagawa; Tetsuaki Shoji; Masahiro Kashima; Hitoki Arisato; Daisuke Morinaga; Tomoo Ikari; Shotaro Ito; Kosuke Tsuji; Hirofumi Takahashi; Toshiaki Shichinohe; Satoshi Konno
    Journal of bronchology & interventional pulmonology, 32, 3, 01 Jul. 2025, [International Magazine]
    English, Scientific journal, BACKGROUND: The convex-probe endobronchial ultrasound (CP-EBUS) bronchoscope is widely used in clinical practice. Despite improvements, the existing CP-EBUS remains limited in accessing areas beyond the mediastinum due to its large distal end diameter, long rigid tip segment, and oblique viewing angle. To address this limitation, Olympus Medical Systems Corporation developed the thin CP-EBUS (TCP-EBUS). This study aimed to compare the accessibility and puncturing ability of TCP-EBUS with existing CP-EBUS in cadaveric models. METHODS: Ten bronchoscopists conducted this study using 2 cadaveric models. The accessibility of TCP-EBUS was evaluated based on the number of bronchial generations that could be reached. To assess the puncturing ability of TCP-EBUS, needle punctures were performed on previously created simulated lesions in the segmental or subsegmental bronchial area, and puncture success rates were calculated. RESULTS: TCP-EBUS demonstrated greater accessibility than CP-EBUS in all segmental bronchi, with statistically significant differences observed in several bronchi (P<0.05). Puncture success rates for simulated lesions using TCP-EBUS were also significantly higher than those using CP-EBUS in both the segmental (85.0% vs. 60.0%, P<0.001) and subsegmental bronchial areas (84.4% vs. 38.9%, P<0.001). In a questionnaire survey, TCP-EBUS was perceived as significantly superior in terms of usability (P<0.05). CONCLUSION: TCP-EBUS has significantly improved both accessibility and puncture performance, providing an advantage over CP-EBUS in segmental and subsegmental bronchial areas. TCP-EBUS has the potential to expand the indications for endobronchial ultrasound-guided transbronchial needle aspiration.
  • Frequency and Prognostic Impact of Local Ablation Therapy for Oligoprogression in Non-Small Cell Lung Cancer.
    Daisuke Morinaga; Jun Sakakibara-Konishi; Ryohei Kamada; Masahiro Kashima; Kosuke Tsuji; Shotaro Ito; Megumi Furuta; Tetsuaki Shoji; Yuta Takashima; Hidenori Kitai; Yasuyuki Ikezawa; Hiroshi Taguchi; Tatsuya Kato; Yoshiki Shinomiya; Kanako C Hatanaka; Yutaka Hatanaka; Satoshi Konno
    Thoracic cancer, 16, 13, e70119, Jul. 2025, [International Magazine]
    English, Scientific journal, BACKGROUND: During the systemic treatment of patients with non-small cell lung cancer (NSCLC), oligoprogression (OP), a condition in which most lesions remain controlled while a few progress or develop, has recently attracted attention. Traditionally, systemic therapy is continued after disease progression; however, advancements in local ablation therapy (LAT), such as radiotherapy and surgery, have demonstrated clinical efficacy in patients with OP. The characteristics of patients who may benefit from LAT or their genetic background remain unclear. This study evaluated the frequency, clinicopathological characteristics, and efficacy of LAT in the treatment of OP. METHODS: A retrospective review was conducted of 510 patients with NSCLC who experienced disease progression after systemic therapy. RESULTS: Overall, 106/510 (23.6%) patients exhibited OP; among these, six patients who received only the best supportive care after OP were excluded. Systemic therapy alone was administered to 79 patients (79.0%), while 21 (21.0%) received LAT. Median local progression-free survival was numerically longer in the LAT group than in the systemic therapy-only group (8.3 and 6.7 months, respectively; p = 0.38). In addition, overall survival was also numerically longer in the LAT group than in the systemic therapy-only group (78.1 and 55.1 months, respectively; p = 0.57). Ribonucleic acid sequencing revealed an increase in extracellular matrix-related gene expression after OP, providing potential molecular insights. CONCLUSIONS: Although this study found no significant prognostic benefit of LAT in patients with OP, future research integrating clinical and molecular data may identify patients most likely to benefit from LAT.
  • 低用量のセルペルカチニブが奏効したRET融合遺伝子陽性非小細胞肺癌の1例
    島田 琉海; 庄司 哲明; 高橋 宏典; 猪狩 智生; 高島 雄太; 古田 恵; 北井 秀典; 池澤 靖元; 榊原 純; 今野 哲; 伊藤 健一郎; 福土 将秀
    肺癌, 65, 3, 205, 205, (NPO)日本肺癌学会, Jun. 2025
    Japanese
  • 術前化学免疫療法1コースで免疫関連有害事象により外科切除に移行し病理学的奏効を得た肺扁平上皮癌の1例
    鎌田 凌平; 庄司 哲明; 池澤 靖元; 久世 瑞穂; 東 陸; 松永 章宏; 畠山 酉季; 辻 康介; 高橋 宏典; 高島 雄太; 古田 恵; 北井 秀典; 榊原 純; 今野 哲; 宮石 陸; 大塚 紀幸; 田中 伸哉; 加藤 達哉
    肺癌, 65, 3, 207, 207, (NPO)日本肺癌学会, Jun. 2025
    Japanese
  • 中枢気道病変に対して行った体外式膜型人工肺(ECMO)導入下呼吸器インターベンションの後方視的検討
    高島 雄太; 品川 尚文; 畠山 酉季; 辻 康介; 伊藤 祥太郎; 中村 友彦; 高橋 宏典; 庄司 哲明; 池澤 靖元; 榊原 純; 新垣 雅人; 加藤 達哉; 相川 勝洋; 内田 洋介; 今野 哲
    気管支学, 47, Suppl., S254, S254, (一社)日本呼吸器内視鏡学会, May 2025
    Japanese
  • Evaluating the Usefulness of the Insertion Tube Rotation Function of Bronchoscope in Cadaver Models.
    Naofumi Shinagawa; Yuta Takashima; Masahiro Kashima; Daisuke Morinaga; Shotaro Ito; Kosuke Tsuji; Mineyoshi Sato; Hirofumi Takahashi; Tetsuaki Shoji; Megumi Furuta; Toshiaki Shichinohe; Satoshi Konno
    Journal of bronchology & interventional pulmonology, 32, 2, 01 Apr. 2025, [International Magazine]
    English, Scientific journal, BACKGROUND: The Olympus bronchoscope is equipped with an insertion tube rotation function; however, data on its usefulness are currently limited. Here, we evaluated the amount of body and wrist movement required by bronchoscopists, the operability of the bronchoscope, and its ease of use with and without the insertion tube rotation function. METHODS: This study was performed on 10 bronchoscopists using 2 cadaveric bodies. The primary endpoint was the amount of movement exerted by the bronchoscopist, which was evaluated using motion capture. We also assessed the deepest bronchial generations that could be reached by the bronchoscope and the time required for insertion. Immediately after the procedures, the bronchoscopists completed a questionnaire to evaluate their perceived difficulty level. RESULTS: The bronchoscopists achieved a 33.5% reduction in wrist rotation (67.8 vs. 110.2 degrees, P<0.05) and a 23.9% reduction in body rotation (17.2 vs. 24.4 degrees, P<0.05) using the insertion tube rotation function for all segmental bronchi. During forceps insertion to simulated lesions, the bronchoscopists' body movement was reduced by 65.1% (11.6 vs. 33.9 degrees, P<0.05), and wrist rotation by 47.6% (63.5 vs. 122.7 degrees, P<0.05). Furthermore, bronchoscopists experienced significantly reduced difficulty inserting biopsy forceps toward simulated target lesions (3.9 vs. 3.2 points, P<0.05) and required less assistance (4.0 vs. 2.0 points, P<0.05) when using the insertion tube rotation function. CONCLUSION: The insertion tube rotation function of the bronchoscope facilitated its insertion and improved operability.
  • 経過中に腹膜播種による腹水が乳び化を呈した,胸腺腫の1例
    武藤 ほの; 庄司 哲明; 古川 貴啓; 辻 康介; 佐藤 峰嘉; 高島 雄太; 古田 恵; 北井 秀典; 池澤 靖元; 木野田 直也; 阿保 大介; 榊原 純; 今野 哲
    日本呼吸器学会誌, 14, 増刊, 366, 366, (一社)日本呼吸器学会, Mar. 2025
    Japanese
  • 気管支狭窄拡張術後にALK-TKIを導入したHIP1-ALK陽性肺癌の1例
    佐藤 祐麻; 北井 秀典; 田上 敬太; 石田 有莉子; 篠崎 鮎香; 佐藤 峰嘉; 高橋 宏典; 古田 恵; 高島 雄太; 庄司 哲明; 池澤 靖元; 榊原 純; 品川 尚文; 今野 哲; 大川 紘弥; 大塚 紀幸; 畑中 佳奈子; 畑中 豊; 横内 浩
    肺癌, 65, 1, 65, 65, (NPO)日本肺癌学会, Feb. 2025
    Japanese
  • 全身療法中にoligoprogression/oligorecurrenceを認めた非小細胞肺癌症例の検討
    鎌田 凌平; 森永 大亮; 榊原 純; 古川 貴啓; 酒井 碧; 佐々木 賢太; 畠山 酉季; 辻 康介; 佐藤 峰嘉; 高橋 宏典; 古田 恵; 庄司 哲明; 高島 雄太; 北井 秀典; 池澤 靖元; 今野 哲; 田口 大志; 加藤 達哉
    肺癌, 65, 1, 66, 67, (NPO)日本肺癌学会, Feb. 2025
    Japanese
  • 小細胞肺癌との鑑別に苦慮した胸部SMARCA4欠損未分化腫瘍の1例
    溝渕 匠平; 榊原 純; 棟方 奈菜; 庄司 哲明; 古田 恵; 高島 雄太; 北井 秀典; 池澤 靖元; 今野 哲; 加藤 憲士郎; 大塚 紀幸; 種井 善一; 田中 伸哉
    肺癌, 65, 1, 67, 67, (NPO)日本肺癌学会, Feb. 2025
    Japanese
  • EGFR遺伝子変異陽性進行再発非小細胞肺癌における免疫チェックポイント阻害剤の治療についての後方視的検討
    古川 貴啓; 庄司 哲明; 酒井 碧; 佐々木 賢太; 畠山 酉季; 辻 康介; 佐藤 峰嘉; 高橋 宏典; 古田 恵; 高島 雄太; 北井 秀典; 池澤 靖元; 榊原 純; 今野 哲
    肺癌, 65, 1, 68, 68, (NPO)日本肺癌学会, Feb. 2025
    Japanese
  • Efficacy and safety of lenvatinib in a case of thymic carcinoma complicated with interstitial lung disease and anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: A case report.
    Yuki Hatakeyama; Jun Sakakibara-Konishi; Masato Tarumi; Kosuke Tsuji; Hirofumi Takahashi; Megumi Furuta; Yuta Takashima; Hidenori Kitai; Tetsuaki Shoji; Yasuyuki Ikezawa; Satoshi Konno
    Respiratory medicine case reports, 54, 102181, 102181, 2025, [International Magazine]
    English, Scientific journal, Based on the results of a multicenter phase II study of patients with previously treated thymic carcinoma, lenvatinib administration for unresectable thymic cancer has been covered under insurance in Japan since 2021. However, patients with interstitial lung disease (ILD) were excluded from that study; therefore, the efficacy and safety of lenvatinib in these patients remain unknown. Herein, we report the case of a woman in her 50s who was diagnosed with thymic carcinoma complicated with ILD. In August 2016, the patient developed ILD with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM). She received triple therapy comprising prednisolone, tacrolimus and azathioprine. In October 2021, the patient complained of lateral chest pain and back pain. In January 2022, computed tomography (CT) revealed an anterior mediastinal tumor, and percutaneous biopsy resulted in a diagnosis of thymic carcinoma with Masaoka classification IVb. In March 2022, first-line treatment with four cycles of carboplatin (area under the curve, 6) + paclitaxel (200 mg/m2) was initiated. Although a partial response was achieved, in September 2022, CT demonstrated progressive disease (PD). Therefore, in October 2022, Lenvatinib (24 mg) was started as the second-line treatment. The best response was stable disease; moreover, although lenvatinib dose reduction was required owing to adverse events, such as biliary-tract infection and stomatitis. The patient did not experience ILD exacerbation. Lenvatinib (14 mg) was continued until PD was observed in March 2023. Our findings suggest that lenvatinib is a viable treatment option for thymic carcinoma with ILD.
  • Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer
    Jun Sakakibara-Konishi; Hirofumi Takahashi; Kenichiro Ito; Tomoo Ikari; Yasuyuki Ikezawa; Hidenori Kitai; Megumi Furuta; Yuta Takashima; Tetsuaki Shoji; Masahide Fukudo; Satoshi Konno
    Respiratory Medicine Case Reports, 53, 102176, 102176, Elsevier BV, 2025, [International Magazine]
    English, Scientific journal, Chromosomal rearrangements of the RET (rearranged during transfection) gene are detected in approximately 1-2% of non-small cell lung cancers (NSCLC) and have function as oncogenic driver genes. Selpercatinib is a highly effective RET inhibitor for RET-rearranged patients with NSCLC and shows mostly tolerable adverse events. However, hypertension, aspartate aminotransferase increase, and alanine aminotransferase increase are the most common adverse events, and dose modification or discontinuation is required occasionally. Here, we describe a case who has response to 40 mg of selpercatinib every other day because the dose had to be adjusted owing to adverse events such as liver dysfunction. Dose modification of selpercatinib, according to adverse event incidences, may be considered, as selpercatinib may be effective in some cases even at very low concentrations.
  • Inhibition of non-homologous end joining mitigates paclitaxel resistance resulting from mitotic slippage in non-small cell lung cancer.
    Kosuke Tsuji; Eiki Kikuchi; Yuta Takashima; Tetsuaki Shoji; Hirofumi Takahashi; Shotaro Ito; Daisuke Morinaga; Masahiro Kashima; Makie Maeda; Hidenori Kitai; Junko Kikuchi; Jun Sakakibara-Konishi; Satoshi Konno
    Cell cycle (Georgetown, Tex.), 22, 17, 1, 11, 17 Aug. 2023, [International Magazine]
    English, Scientific journal, Mitotic slippage, which enables cancer cells to bypass cell death by transitioning from mitosis to the G1 phase without undergoing normal cytokinesis, is one likely mechanism of paclitaxel (PTX) resistance. DNA double-strand breaks (DSBs) in the G1 phase are mainly repaired through non-homologous end joining (NHEJ). Therefore, inhibiting NHEJ could augment the PTX-induced cytotoxicity by impeding the repair of PTX-induced DSBs during the G1 phase following mitotic slippage. We aimed to evaluate the effects of NHEJ inhibition on mitotic slippage after PTX treatment in non-small cell lung cancer (NSCLC). H1299, A549, H1975, and H520 NSCLC cell lines were employed. In addition, A-196 and JQ1 were used as NHEJ inhibitors. H1299 cells were PTX-resistant and exhibited an increased frequency of mitotic slippage upon PTX treatment. NHEJ inhibitors significantly augmented the PTX-induced cytotoxicity, DSBs, and apoptosis in H1299 cells. The newly generated PTX-resistant cells were even more prone to mitotic slippage following PTX treatment and susceptible to the combined therapy. Docetaxel further demonstrated synergistic effects with the NHEJ inhibitor in PTX-resistant cells. NHEJ inhibition may overcome intrinsic or acquired PTX resistance resulting from mitotic slippage by synergistically increasing the cytotoxic effects of antimitotic drugs in NSCLC.
  • 抗血小板薬・抗凝固薬内服患者における経気管支生検の有害事象の検討
    庄司 哲明; 品川 尚文; 高島 雄太; 菊池 創; 池澤 靖元; 高階 太一; 今野 哲
    気管支学, 45, 2, 89, 97, (NPO)日本呼吸器内視鏡学会, Mar. 2023
    Japanese
  • Endobronchial ultrasound with a guide sheath during bronchoscopy for peripheral pulmonary lesions.
    Yuta Takashima; Masahide Oki
    Expert review of respiratory medicine, 17, 10, 929, 936, 2023, [International Magazine]
    English, Scientific journal, INTRODUCTION: Radial probe endobronchial ultrasound (rEBUS) improves the diagnostic yield of peripheral pulmonary lesions (PPLs). A notable methodological limitation of rEBUS is that it does not provide real-time images during transbronchial biopsy (TBB) procedures. To overcome this limitation, a guide sheath (GS) method was developed. AREAS COVERED: This review covers the procedures and complications of rEBUS-guided TBB with a GS (EGS method). We also present the data from key randomized controlled trials (RCTs) of the EGS method and summarize the usefulness of combining the EGS method with various techniques. Finally, we discuss in which situations EGS should be used. EXPERT OPINION: A large RCT showed that the diagnostic yield of the EGS method for PPLs was significantly higher than that of rEBUS-guided TBB without a GS (non-GS method). However, since the EGS and non-GS methods each have their own advantages and disadvantages, they should be considered complementary and used flexibly in different cases. In some cases, a combination of the two may be an option. The appropriate combination of EGS with various techniques may enhance the diagnostic yield of PPLs and help prevent complications. The choice should be based on the location and texture of the target lesion, as well as operator skill, resource availability, safety, and accuracy.
  • EGFR inhibition in EGFR-mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment.
    Akihiko Shiiya; Takuro Noguchi; Utano Tomaru; Shin Ariga; Yuta Takashima; Yoshihito Ohhara; Jun Taguchi; Satoshi Takeuchi; Yasushi Shimizu; Ichiro Kinoshita; Tomonobu Koizumi; Yoshihiro Matsuno; Naofumi Shinagawa; Jun Sakakibara-Konishi; Hirotoshi Dosaka-Akita
    Cancer science, 114, 4, 1270, 1283, 18 Dec. 2022, [International Magazine]
    English, Scientific journal, Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) elicit potent cell cycle arrest in EGFR-mutant non-small-cell lung cancer (NSCLC) cells. However, little is known about the mechanisms through which these drugs alter the tumor phenotype that contributes to the immune escape of EGFR-mutant cells. Using EGFR-mutant NSCLC cell lines and tissue samples from patients, we investigated the changes in immune checkpoints expressed in tumor cells following EGFR inhibition. Subsequently, we also analyzed the role of soluble factors from the dying tumor cells in the activation of immune signaling pathways involved in therapy resistance. Upon EGFR-TKI treatment, we found that EGFR-mutant cells upregulated the expression of innate immune checkpoint CD24 in vitro. We then analyzed biopsy samples from six patients who developed resistance to a first-generation EGFR-TKI without the acquired T790M mutation. Immunohistochemistry revealed that levels of tumor CD24 expression were increased upon treatment compared with those from pre-treatment samples. Monocyte-derived macrophages facilitated antibody-dependent cellular phagocytosis when EGFR-TKI-treated EGFR-mutant cells were incubated with anti-CD24 antibodies in vitro, suggesting that CD24 may be a therapeutical target for EGFR-mutant lung cancer. Moreover, EGFR inhibition accelerated the release of cell-free DNA (cfDNA) from dying tumor cells, which activated the type I interferon signaling pathways in human THP-1 monocytes in a stimulator of interferon genes-dependent manner. Our study indicates that EGFR inhibition in EGFR-mutant NSCLC cells fosters a tumor microenvironment associated with immune escape. Thus, CD24 targeted therapy and cfDNA monitoring may contribute to improved treatment outcomes in patients with EGFR-mutant NSCLC.
  • Risk of bleeding associated with transbronchial biopsy using flexible bronchoscopy in patients with echocardiographic or chest CT evidence of pulmonary hypertension.
    Yuta Takashima; Naofumi Shinagawa; Daisuke Morinaga; Junichi Nakamura; Megumi Furuta; Tetsuaki Shoji; Hajime Asahina; Eiki Kikuchi; Junko Kikuchi; Jun Sakakibara-Konishi; Ichizo Tsujino; Satoshi Konno
    BMC pulmonary medicine, 22, 1, 449, 449, 28 Nov. 2022, [International Magazine]
    English, Scientific journal, BACKGROUND: Endobronchial ultrasound (EBUS)-guided transbronchial biopsy (TBB) facilitates the diagnosis of various respiratory diseases. The safety of performing EBUS-guided TBB in patients with a finding of pulmonary hypertension (PH) is controversial. Little is known about the relationship between the risk of bleeding associated with EBUS-guided TBB in the presence of PH suspected on echocardiography or chest CT. METHODS: To assess the risk of bleeding associated with EBUS-guided TBB in patients with presumed PH per echocardiography or chest CT, we retrospectively reviewed the medical records of 314 consecutive patients who underwent EBUS-guided TBB using a guide sheath (GS), as well as echocardiography and chest CT. Bleeding complication was defined as over one minute of suctioning; repeated wedging of the bronchoscope; instillation of cold saline, diluted vasoactive substances, or thrombin due to persistent bleeding. Findings of suspected PH were defined as peak tricuspid regurgitation velocity (TRV) > 2.8 m/s on echocardiography or pulmonary artery to aorta ratio (PA:A ratio) > 0.9 on chest CT. RESULTS: In total, 35 (11.1%) patients developed bleeding, and all cases were managed safely. Furthermore, 17 (5.4%) and 59 (18.8%) patients were suspected to have PH based on echocardiography and chest CT, respectively. Among the patients suspected to have PH on echocardiography, five (5/17 = 29.4%) patients developed bleeding. Among the patients suspected to have PH on chest CT, 11 (11/59 = 18.6%) patients developed bleeding. Univariate analysis revealed that long diameter (≥ 30 mm) of the lesion, lesion location (the biopsy site was inner than the segmental bronchus), bronchoscopic diagnosis of malignancy, and additional biopsy were potential predictive factors for bleeding. The finding of suspected PH on echocardiography correlated significantly with bleeding (p = 0.03). On multivariate analysis, long diameter (≥ 30 mm) of the lesion (p = .021) and findings of suspected PH on echocardiography (p = .049) were significantly associated with bleeding. CONCLUSION: All cases of bleeding in the present study were managed safely. The risk of bleeding is moderately elevated when PH is suspected by echocardiography in patients undergoing EBUS-guided TBB using a GS.
  • 非小細胞肺癌のmitotic slippageに対するDNA修復阻害の有用性についての基礎的検討(Inhibition of DNA damage repair for mitotic slippage after paclitaxel treatment in non-small cell lung cancer)
    辻 康介; 菊地 英毅; 高島 雄太; 庄司 哲明; 朝比奈 肇; 菊地 順子; 品川 尚文; 榊原 純; 今野 哲
    日本癌学会総会記事, 81回, P, 1063, (一社)日本癌学会, Sep. 2022
    English
  • オシメルチニブ長期内服中に亜鉛欠乏に伴う壊死性遊走性紅斑様皮疹を生じた一例
    山本 岳; 朝比奈 肇; 岩田 浩明; 高桑 恵美; 伊藤 祥太郎; 國崎 守; 高島 雄太; 菊地 順子; 菊地 英毅; 榊原 純; 品川 尚文; 今野 哲
    日本呼吸器学会誌, 11, 増刊, 303, 303, (一社)日本呼吸器学会, Apr. 2022
    Japanese
  • Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study.
    Tomoyasu Mimori; Takehito Shukuya; Ryo Ko; Yusuke Okuma; Tomonobu Koizumi; Hisao Imai; Yuichi Takiguchi; Eisaku Miyauchi; Hiroshi Kagamu; Tomohide Sugiyama; Keisuke Azuma; Yukiko Namba; Masahiro Yamasaki; Hisashi Tanaka; Yuta Takashima; Sayo Soda; Osamu Ishimoto; Nobuyuki Koyama; Kunihiko Kobayashi; Kazuhisa Takahashi
    Cancers, 14, 2, 11 Jan. 2022, [International Magazine]
    English, Scientific journal, The optimal tumor marker for predicting the prognosis of advanced thymic carcinoma (ATC) remains unclear. We conducted a multi-institutional retrospective study of patients with ATC. A total of 286 patients were treated with chemotherapy. Clinicopathological information, including serum tumor markers, was evaluated to determine the overall survival (OS) and progression-free survival (PFS). The carcinoembryonic antigen, cytokeratin-19 fragment, squamous cell carcinoma (SCC) antigen, progastrin-releasing peptide, neuron-specific enolase (NSE), and alpha-fetoprotein levels were evaluated. In the Kaplan-Meier analysis, the OS was significantly shorter in the patients with elevated NSE levels than in those with normal NSE levels (median, 20.3 vs. 36.8 months; log-rank test p = 0.029; hazard ratio (HR), 1.55; 95% confidence interval (CI), 1.05-2.31 (Cox proportional hazard model)); a similar tendency regarding the PFS was observed (median, 6.4 vs. 11.0 months; log-rank test p = 0.001; HR, 2.04; 95% CI, 1.31-3.18). No significant differences in the OS and PFS were observed among the other tumor markers. In both univariate and multivariate analyses of the patients with SCC only, the NSE level was associated with the OS and PFS. Thus, the NSE level may be a prognostic tumor marker for thymic carcinoma, regardless of histology.
  • A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer.
    Hiroyuki Yasuda; Eiki Ichihara; Jun Sakakibara-Konishi; Yoshitaka Zenke; Shinji Takeuchi; Masahiro Morise; Katsuyuki Hotta; Mineyoshi Sato; Shingo Matsumoto; Azusa Tanimoto; Reiko Matsuzawa; Katuyuki Kiura; Yuta Takashima; Seiji Yano; Junji Koyama; Takahiro Fukushima; Junko Hamamoto; Hideki Terai; Shinnosuke Ikemura; Ryo Takemura; Koichi Goto; Kenzo Soejima
    Lung cancer (Amsterdam, Netherlands), 162, 140, 146, Dec. 2021, [International Magazine]
    English, Scientific journal, OBJECTIVES: Several preclinical data proposed a potential efficacy of osimertinib, a third-generation EGFR tyrosine kinase inhibitor, for EGFR exon 20 insertion (EGFR ex20ins)-positive non-small cell lung cancer (NSCLC). However, reported case series and a retrospective study proposed controversial efficacy. The efficacy of osimertinib in EGFR ex20ins-positive NSCLC have not been well evaluated in prospective clinical trials. In this study, we performed a prospective, single-arm, multi-center, open-label, non-randomized phase I/II study to evaluate efficacy of osimertinib for EGFR ex20ins-positive NSCLC. MATERIALS AND METHODS: From August 2018 to January 2020, 14 NSCLC patients with EGFR ex20ins were enrolled, of whom 2 were excluded because they did not meet the inclusion criteria. Efficacy and safety of 80 mg osimertinib were evaluated. In addition, we performed a translational exploratory study to clarify the association of mutation type-specific drug sensitivity, osimertinib pharmacokinetic data, and clinical efficacy. RESULTS: Of the evaluated patients, none experienced objective response, 7 experienced stable disease (58.3%), and 5 experienced disease progression (41.7%). The median progression free survival (PFS) was 3.8 months, and the median overall survival was 15.8 months. Interestingly, the exploratory study demonstrated statistically significant positive correlation between plasma osimertinib concentration/in vitro IC50 ratio and PFS (R = 0.9912, P = 0.0001), highlighting the mutation type-specific concentration-dependent efficacy of osimertinib for EGFR ex20ins-positive NSCLC. CONCLUSIONS: Regular dose, 80 mg/day, of osimertinib has limited clinical activity in NSCLC patients with EGFR ex20ins. The translational study proposed the potential efficacy of higher dose osimertinib in a subgroup of EGFR ex20ins-positive NSCLC.
  • 肺動脈圧の上昇が疑われる症例でのEBUS-GS-TBBに伴う出血に関する検討
    高島 雄太; 品川 尚文; 山本 岳; 森永 大亮; 古田 恵; 庄司 哲明; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 中村 順一; 辻野 一三; 今野 哲
    気管支学, 43, 6, 690, 690, (一社)日本呼吸器内視鏡学会, Nov. 2021
    Japanese
  • Surgical treatment for tracheal stent prolapse in a patient with blunt tracheal trauma.
    Shinya Otsuka; Tatsuya Kato; Hideki Ujiie; Aki Fujiwara-Kuroda; Yasuhiro Hida; Kichizo Kaga; Satoru Wakasa; Yuta Takashima; Naofumi Shinagawa
    General thoracic and cardiovascular surgery, 69, 12, 1589, 1592, 28 Sep. 2021, [Domestic magazines]
    English, Scientific journal, Blunt tracheal injury is a rare but life-threatening condition. Several indications for treatment have been reported. Conservative treatment (i.e., stenting) can be performed when the patient is clinically stable or has medical contraindications to surgical treatment. Although some studies have reported the use of tracheal stents as treatment for iatrogenic injury and blunt trauma, the efficacy of these stents is unknown. Herein, we report a case of emergency tracheoplasty for the management of tracheal stent prolapse in a patient with blunt tracheobronchial trauma. This report highlights the necessity of being cautious about the migration and prolapse of tracheal stents, which can more frequently occur in blunt trauma than in malignant stenosis or iatrogenic injury. Due to the limitations of non-surgical treatments, early surgical intervention may be lifesaving.
  • 当科における悪性胸膜中皮腫に対するニボルマブ投与症例の検討
    西村 弘基; 古田 恵; 辻 康介; 葛巻 哲; 児島 裕一; 山本 岳; 伊藤 祥太郎; 國崎 守; 高島 雄太; 庄司 哲明; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 品川 尚文; 今野 哲
    肺癌, 61, 1, 64, 64, (NPO)日本肺癌学会, Feb. 2021
    Japanese
  • Evaluating the immunoproteasome as a potential therapeutic target in cisplatin-resistant small cell and non-small cell lung cancer.
    Tetsuaki Shoji; Eiki Kikuchi; Junko Kikuchi; Yuta Takashima; Megumi Furuta; Hirofumi Takahashi; Kosuke Tsuji; Makie Maeda; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Jun Sakakibara-Konishi; Satoshi Konno
    Cancer chemotherapy and pharmacology, 85, 5, 843, 853, 30 Mar. 2020, [Peer-reviewed], [International Magazine]
    English, Scientific journal, PURPOSE: We evaluated the expression of proteasome subunits to assess whether the proteasome could be a therapeutic target in cisplatin-resistant lung cancer cells. METHODS: Cisplatin-resistant (CR) variants were established from three non-small cell lung cancer (NSCLC) cell lines (A549, H1299, and H1975) and two small cell lung cancer (SCLC) cell lines (SBC3 and SBC5). The expression of proteasome subunits, the sensitivity to immunoproteasome inhibitors, and 20S proteasomal proteolytic activity were examined in the CR variants of the lung cancer cell lines. RESULTS: All five CR cell lines highly expressed one or both of the immunoproteasome subunit genes, PSMB8 and PSMB9, while no clear trend was observed in the expression of constitutive proteasome subunits. The CR cells expressed significantly higher levels of PSMB8 and PSMB9 proteins, as well. The CR variants of the H1299 and SBC3 cell lines were more sensitive to immunoproteasome inhibitors, and had significantly more proteasomal proteolytic activity than their parental counterparts. CONCLUSIONS: The immunoproteasome may be an effective therapeutic target in a subset of CR lung cancers. Proteasomal proteolytic activity may be a predictive marker for the efficacy of immunoproteasome inhibitors in cisplatin-resistant SCLC and NSCLC.
  • Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer.
    Yuta Takashima; Eiki Kikuchi; Junko Kikuchi; Motofumi Suzuki; Hajime Kikuchi; Makie Maeda; Tetsuaki Shoji; Megumi Furuta; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Jun Sakakibara-Konishi; Satoshi Konno
    International journal of cancer, 146, 4, 1114, 1124, 15 Feb. 2020, [Peer-reviewed], [International Magazine]
    English, Scientific journal, Bromodomain and extraterminal domain (BET) inhibitors are broadly active against distinct types of cancer, including nonsmall cell lung cancer (NSCLC). Previous studies have addressed the effect of BET-inhibiting drugs on the expression of oncogenes such as c-Myc, but DNA damage repair pathways have also been reported to be involved in the efficacy of these drugs. AZD1775, an inhibitor of the G2-M cell cycle checkpoint kinase WEE1, induces DNA damage by promoting premature mitotic entry. Thus, we hypothesized that BET inhibition would increase AZD1775-induced cytotoxicity by impairing DNA damage repair. Here, we demonstrate that combined inhibition of BET and WEE1 synergistically suppresses NSCLC growth both in vitro and in vivo. Two BET inhibitors, JQ1 and AZD5153, increased and prolonged AZD1775-induced DNA double-strand breaks (DSBs) and concomitantly repressed genes related to nonhomologous end joining (NHEJ), including XRCC4 and SHLD1. Furthermore, pharmaceutical inhibition of BET or knockdown of the BET protein BRD4 markedly diminished NHEJ activity, and the BET-inhibitor treatment also repressed myelin transcription factor 1 (MYT1) expression and promoted mitotic entry with subsequent mitotic catastrophe when combined with WEE1 inhibition. Our findings reveal that BET proteins, predominantly BRD4, play an essential role in DSB repair through the NHEJ pathway, and further suggest that combined inhibition of BET and WEE1 could serve as a novel therapeutic strategy for NSCLC.
  • DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail.
    Megumi Furuta; Hajime Kikuchi; Tetsuaki Shoji; Yuta Takashima; Eiki Kikuchi; Junko Kikuchi; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Jun Sakakibara-Konishi
    Cancer science, 110, 5, 1599, 1608, May 2019, [Peer-reviewed], [International Magazine]
    English, Scientific journal, Delta-like protein 3 (DLL3) is a ligand of Notch signaling, which mediates cell-fate decisions and is tumor-suppressive or oncogenic depending on the cellular context. Previous studies show that DLL3 is highly expressed in small cell lung cancer (SCLC) but not in normal lung tissue, suggesting that DLL3 might be associated with neuroendocrine tumorigenesis. However, its role in SCLC remains unclear. To investigate the role of DLL3 in tumorigenesis in SCLC, we performed loss-of-function and gain-of-function assays using SCLC cell lines. In vitro analysis of cell migration and invasion by transwell assay showed that DLL3 knockdown reduced migration and invasion of SCLC cells, whereas DLL3 overexpression increased these activities. In addition, DLL3 positively regulated SNAI1 expression and knockdown of SNAI1 attenuated the migration and invasion ability of SCLC cells. Moreover, upregulated DLL3 expression induced subcutaneous tumor growth in mouse models. These results indicate that DLL3 promoted tumor growth, migration and invasion in an SCLC model by modulating SNAI1/Snail.
  • Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study.
    Ko R; Shukuya T; Okuma Y; Tateishi K; Imai H; Iwasawa S; Miyauchi E; Fujiwara A; Sugiyama T; Azuma K; Muraki K; Yamasaki M; Tanaka H; Takashima Y; Soda S; Ishimoto O; Koyama N; Morita S; Kobayashi K; Nukiwa T; Takahashi K; North East Japan; Study Group
    The oncologist, 23, 10, 1210, 1217, Oct. 2018, [Peer-reviewed], [International Magazine]
    English, Scientific journal, BACKGROUND: The prognostic factors and the efficacy of first-line chemotherapy remain unclear in patients with advanced thymic carcinoma. MATERIALS AND METHODS: We conducted a multi-institutional retrospective study named NEJ023 for patients with advanced thymic carcinoma. All patients without any indication of curative treatment were treated with chemotherapy from 1995 to 2014 at 40 institutions of the North East Japan Study Group. RESULTS: A total of 286 patients with advanced thymic carcinoma were analyzed. First-line chemotherapy included platinum-based doublets in 62.2% of the patients, monotherapy in 3.5%, and other multidrug chemotherapy (e.g., cisplatin, doxorubicin, vincristine, and cyclophosphamide [ADOC]) in 34.3%. The median follow-up period was 55.5 months, and the median overall survival (OS) from the start of first-line chemotherapy was 30.7 months (95% confidence interval, 25.9-35.9 months). There was no significant difference in OS among different first-line chemotherapy regimens (e.g., between carboplatin/paclitaxel and ADOC, median OS: 27.8 vs. 29.9 months). Masaoka-Koga stage IVa and volume reduction surgery were favorable prognostic factors for OS in the multivariate analysis using the Cox proportional hazards model. CONCLUSION: The efficacy of each first-line chemotherapy regimen for advanced thymic carcinoma did not vary significantly. Our results might support the adequacy of the use of carboplatin/paclitaxel as first-line chemotherapy for these patients. IMPLICATIONS FOR PRACTICE: Because of its rarity, there is limited information about prognostic factors and efficacy of chemotherapy in patients with advanced thymic carcinoma. This is the largest data set for those patients treated with chemotherapy. This study suggests there is no significant difference in efficacy between carboplatin/paclitaxel and cisplatin/doxorubicin/vincristine/cyclophosphamide for advanced thymic carcinoma. This result can support the adequacy of the selection of platinum doublets as treatment for those patients, rather than anthracycline-based multidrug regimen.
  • Clinicopathologic Features and Immune Microenvironment of Non-Small-cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Yuta Takashima; Jun Sakakibara-Konishi; Yutaka Hatanaka; Kanako C Hatanaka; Yoshihito Ohhara; Satoshi Oizumi; Yasuhiro Hida; Kichizo Kaga; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Yoshihiro Matsuno; Masaharu Nishimura
    Clinical lung cancer, 19, 4, 352, 359, Jul. 2018, [Peer-reviewed], [International Magazine]
    English, Scientific journal, BACKGROUND: Approximately 20% to 30% of non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)-activating mutations are not responsive to EGFR tyrosine kinase inhibitors (TKIs). Although primary resistance to EGFR-TKIs has been attributed to various genetic alterations, little is known about the clinical and immunopathologic features of patients with primary resistance. The tumor immune microenvironment, including tumor-infiltrating lymphocytes (TILs) and programmed cell death ligand 1 (PD-L1), has been reported to play an important role in tumor progression in those with NSCLC. However, few studies have directly focused on the relationship between the tumor immune microenvironment and primary resistance to EGFR-TKIs. MATERIALS AND METHODS: The characteristics of 124 NSCLC patients with EGFR mutations who had received EGFR-TKIs were analyzed. Primary resistance was defined as disease progression within 3 months after EGFR-TKI treatment. Tumor specimens obtained before EGFR-TKI treatment were assessed for the density of TILs expressing CD4 or CD8 and for the expression rate of PD-L1 on tumor cells and tumor-infiltrating immune cells, immunohistochemically. RESULTS: Primary resistance was observed in 13.7% of the patients (17 of 124). A significant difference in smoking history was observed between patients with primary resistance and those with non-primary resistance. A lower density of total TILs and negative PD-L1 expression on immunohistochemical analysis correlated significantly with primary resistance, in contrast to that with non-primary resistance. Moreover, the negative PD-L1 expression with low TIL density, indicating immune ignorant phenotype of tumor microenvironment, was observed in those with primary resistance with a significant difference. CONCLUSION: Smoking and immune ignorance in the tumor microenvironment might result in primary resistance to EGFR-TKIs.
  • Successful Application of Edoxaban in the Treatment of Venous Thromboembolism Recurrence in a Patient with Non-small Cell Lung Cancer after Tumor Shrinkage.
    Tetsuaki Shoji; Hidenori Mizugaki; Yasuyuki Ikezawa; Megumi Furuta; Yuta Takashima; Hajime Kikuchi; Houman Goudarzi; Hajime Asahina; Junko Kikuchi; Eiki Kikuchi; Jun Sakakibara-Konishi; Naofumi Shinagawa; Ichizo Tsujino; Masaharu Nishimura
    Internal medicine (Tokyo, Japan), 57, 12, 1769, 1772, 15 Jun. 2018, [Peer-reviewed], [Domestic magazines]
    English, Scientific journal, This report describes the case of a 66-year-old man with non-small cell lung cancer and venous thromboembolism (VTE). Unfractionated heparin (UFH) was initially used to control VTE before chemotherapy. However, switching UFH to warfarin or edoxaban, a novel oral anticoagulant (NOAC), failed. Chemotherapy was then administered to control the tumor which was thought to have been the main cause of VTE, which had been treated by UFH. After tumor shrinkage was achieved by chemotherapy, we were able to successfully switch from UFH to edoxaban. Controlling the tumor size and activity enabled the use of edoxaban as maintenance therapy for VTE.
  • Diversities and similarities in pH dependency among bacterial NhaB-like Na+/H+ antiporters.
    Wakako Kiriyama; Kei Honma; Tomoaki Hiratsuka; Itsuka Takahashi; Takahiro Nomizu; Yuta Takashima; Masataka Ohtsuka; Daiki Takahashi; Kazuya Moriyama; Sayoko Mori; Shiho Nishiyama; Masahiro Fukuhara; Tatsunosuke Nakamura; Toru Shigematsu; Toshio Yamaguchi
    Microbiology (Reading, England), 159, Pt 10, 2191, 2199, Oct. 2013, [International Magazine]
    English, Scientific journal, NhaB-like antiporters were the second described class of Na(+)/H(+) antiporters, identified in bacteria more than 20 years ago. While nhaB-like gene sequences have been found in a number of bacterial genomes, only a few of the NhaB-like antiporters have been functionally characterized to date. Although earlier studies have identified a few pH-sensitive and -insensitive NhaB-like antiporters, the mechanisms that determine their pH responses still remain elusive. In this study, we sought to investigate the diversities and similarities among bacterial NhaB-like antiporters, with particular emphasis on their pH responsiveness. Our phylogenetic analysis of NhaB-like antiporters, combined with pH profile analyses of activities for representative members of several phylogenetic groups, demonstrated that NhaB-like antiporters could be classified into three distinct types according to the degree of their pH dependencies. Interestingly, pH-insensitive NhaB-like antiporters were only found in a limited proportion of enterobacterial species, which constitute a subcluster that appears to have diverged relatively recently among enterobacterial NhaB-like antiporters. Furthermore, kinetic property analyses of NhaB-like antiporters at different pH values revealed that the degree of pH sensitivity of antiport activities was strongly correlated with the magnitude of pH-dependent change in apparent Km values, suggesting that the dramatic pH sensitivities observed for several NhaB-like antiporters might be mainly due to the significant increases of apparent Km at lower pH. These results strongly suggested the possibility that the loss of pH sensitivity of NhaB-like antiporters had occurred relatively recently, probably via accumulation of the mutations that impair pH-dependent change of Km in the course of molecular evolution.
■ Other Activities and Achievements
■ Syllabus
  • 基本医学研究, 2024年, 修士課程, 医学院
  • 基本医学総論, 2024年, 修士課程, 医学院
  • 医学総論, 2024年, 博士後期課程, 医学院
  • 基盤医学研究, 2024年, 博士後期課程, 医学院
  • 臨床医学研究, 2024年, 博士後期課程, 医学院
■ Research Themes
  • BET阻害によるDNA損傷修復阻害効果を用いた新たな肺癌治療の開発
    科学研究費助成事業 若手研究
    01 Apr. 2020 - 31 Mar. 2023
    高島 雄太
    近年、BET阻害がDNA2本鎖切断(DSB)の修復を阻害することでDNA傷害活性をもつ様々な薬剤の効果を増強することが報告されている。しかし、これらの先行研究のほとんどは細胞周期におけるS期細胞のDNAを傷害する薬剤とBET阻害剤との併用についての検討であり、その標的としているDSB修復機構は相同組換え(HR)である。BET阻害はもう一つのDSB修復機構である非相同末端結合機構(NHEJ)も抑制しうることが報告されているが、その機序やBET阻害によるNHEJ阻害能が抗癌治療に応用できるかどうかについての検討はほとんどされていない。本研究は肺癌の新たな治療法を産み出すべく、BET阻害によるNHEJ抑制を利用した治療方法の有 用性とその機序の解明を目指す。申請者らはNHEJレポータープラスミドを組み込んだ非小細胞肺癌細胞株の作成に成功し、その細胞株を用いてBET阻害がNHEJ修復活性を著明に低下させることを明らかにした。また、非小細胞肺癌細胞株にBET阻害剤を投与するとNHEJに関与する複数の遺伝子の発現が低下することも明らかにした。DSBを起こすことが知られているWEE1阻害剤とBET阻害剤を非小細胞肺癌細胞株に対して併用投与すると、それぞれの薬剤を単独投与した際と比較しても強いDSBが生じることが明らかとなり、この2剤併用療法は非小細胞肺癌細胞株に対して相乗的な抗腫瘍効果を示した。異種移植マウスモデルを用いた実験でも細胞実験と矛盾しない結果であった。これらの結果から、BET阻害剤とWEE1阻害剤の併用療法は非小細胞肺癌細胞に対する新しい治療戦略になる可能性が示唆された。今後、BET阻害が細胞周期に及ぼす影響などさらなる検証を進めていく予定である。
    日本学術振興会, 若手研究, 北海道大学, 20K17173
  • The study of the impact of BET inhibition on NHEJ DNA damage repair and a new treatment strategy using BET inhibitors for lung cancer
    Grants-in-Aid for Scientific Research Grant-in-Aid for Research Activity Start-up
    30 Aug. 2019 - 31 Mar. 2021
    Takashima Yuta
    We show that combined inhibition of BET and WEE1 synergistically suppresses NSCLC growth. BET inhibition considerably repressed NHEJ pathway-related genes and diminished NHEJ pathway-mediated DNA double-strand break repair. Furthermore, BET inhibition repressed MYT1 expression and promoted mitotic entry when combined with WEE1 inhibition. This is the first report to show that BET inhibition synergizes with WEE1 inhibitor via two distinct mechanisms, impairing NHEJ DNA damage repair and synergistic forced mitotic entry.
    Japan Society for the Promotion of Science, Grant-in-Aid for Research Activity Start-up, Hokkaido University, 19K23876